A Change of Heart: Emerging Strategies in the Management of CV Risk in Type 2 Diabetes

A Change of Heart: Emerging Strategies in the Management of CV Risk in Type 2 Diabetes

In patients with type 2 diabetes & established cardiovascular disease (CVD) or CVD risk, large cardiovascular outcome trials have demonstrated improved cardiovascular outcomes with the following antihyperglycemic agents: Untitled multiple choice question

  • A. Empagliflozin
  • B. Liraglutide
  • C. Canagliflozin
  • D. Lixisenatide
  • E. A, B and C
  • F. All of the above

Diabetes Canada recommends that the following antihyperglycemic agent(s) with demonstrated CV outcome benefits be added in patients with type 2 diabetes and clinical cardiovascular disease (CVD):

  • A. Empagliflozin
  • B. Liraglutide
  • C. Canagliflozin
  • D. A and B only
  • E. All of the above